Drugs that contain Varenicline Tartrate

1. List of Chantix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6890927 PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
May, 2022

(8 months ago)

US7265119 PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Aug, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6890927

(Pediatric)

PF PRISM CV Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Nov, 2022

(2 months ago)

US7265119

(Pediatric)

PF PRISM CV Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
Feb, 2023

(12 hours from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
Pediatric Exclusivity (PED) Aug 22, 2022

Market Authorisation Date: 10 May, 2006

Treatment: Aid to smoking cessation

Dosage: TABLET;ORAL

How can I launch a generic of CHANTIX before it's patent expiration?
More Information on Dosage

2. List of Tyrvaya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504644 OYSTER POINT PHARMA Methods of increasing tear production
Oct, 2035

(12 years from now)

US11224598 OYSTER POINT PHARMA Methods of increasing lacrimal proteins
Oct, 2035

(12 years from now)

US9504645 OYSTER POINT PHARMA Pharmaceutical formulations for treating ocular conditions
Oct, 2035

(12 years from now)

US10456396 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(12 years from now)

US9597284 OYSTER POINT PHARMA Dry eye treatments
Oct, 2035

(12 years from now)

US9532944 OYSTER POINT PHARMA Methods of improving ocular discomfort
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 15, 2024

Market Authorisation Date: 15 October, 2021

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in